Journal ArticleDOI
Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma
Rui-Hua Xu,Wei Wei,Wei Wei,Michal Krawczyk,Wenqiu Wang,Huiyan Luo,Huiyan Luo,Ken Flagg,Shaohua Yi,William Shi,Qingli Quan,Kang Li,Lianghong Zheng,Heng Zhang,Bennett A. Caughey,Qi Zhao,Jiayi Hou,Runze Zhang,Yanxin Xu,Huimin Cai,Gen Li,Rui Hou,Zheng Zhong,Danni Lin,Xin Fu,Jie Zhu,Yaou Duan,Meixing Yu,Binwu Ying,Wengeng Zhang,Juan Wang,Edward Zhang,Charlotte Zhang,Oulan Li,Rongping Guo,Hannah Carter,Jian-Kang Zhu,Xiaoke Hao,Kang Zhang,Kang Zhang,Kang Zhang +40 more
TLDR
This work identified an HCC-specific methylation marker panel by comparing HCC tissue and normal blood leukocytes and showed that methylation profiles of HCC tumour DNA and matched plasma ctDNA are highly correlated.Abstract:
An effective blood-based method for the diagnosis and prognosis of hepatocellular carcinoma (HCC) has not yet been developed. Circulating tumour DNA (ctDNA) carrying cancer-specific genetic and epigenetic aberrations may enable a noninvasive 'liquid biopsy' for diagnosis and monitoring of cancer. Here, we identified an HCC-specific methylation marker panel by comparing HCC tissue and normal blood leukocytes and showed that methylation profiles of HCC tumour DNA and matched plasma ctDNA are highly correlated. Using cfDNA samples from a large cohort of 1,098 HCC patients and 835 normal controls, we constructed a diagnostic prediction model that showed high diagnostic specificity and sensitivity (P < 0.001) and was highly correlated with tumour burden, treatment response, and stage. Additionally, we constructed a prognostic prediction model that effectively predicted prognosis and survival (P < 0.001). Together, these findings demonstrate in a large clinical cohort the utility of ctDNA methylation markers in the diagnosis, surveillance, and prognosis of HCC.read more
Citations
More filters
Journal ArticleDOI
Molecular therapies and precision medicine for hepatocellular carcinoma
TL;DR: Treatment advances have been made in the past few years, and further advancements are expected in the near future, including biomarker-driven treatments and immunotherapies, as discussed in this Review.
Journal ArticleDOI
From NASH to HCC: current concepts and future challenges.
Quentin M. Anstee,Quentin M. Anstee,Helen L. Reeves,Helen L. Reeves,Elena Kotsiliti,Olivier Govaere,Mathias Heikenwalder +6 more
TL;DR: This Review discusses NAFLD-associated HCC, including its epidemiology, key features that promote hepatocarcinogenesis and the management of HCC in patients with obesity and associated metabolic comorbidities, and the challenges and future directions of research.
Journal ArticleDOI
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma
Ting Li,Pei Shan Hu,Zhixiang Zuo,Jin Fei Lin,Xingyang Li,Qi Nian Wu,Zhan Hong Chen,Zhao Lei Zeng,Feng Wang,Jian Zheng,Demeng Chen,Bo Li,Tie Bang Kang,Dan Xie,Dongxin Lin,Dongxin Lin,Huai-Qiang Ju,Rui-Hua Xu +17 more
TL;DR: This study revealed that METTL3, acting as an oncogene, maintained SOX2 expression through an m6A-IGF2BP2-dependent mechanism in CRC cells, and indicated a potential biomarker panel for prognostic prediction in CRC.
Journal ArticleDOI
Tumour evolution in hepatocellular carcinoma.
Amanda J. Craig,Johann von Felden,Johann von Felden,Teresa Garcia-Lezana,Samantha Sarcognato,Samantha Sarcognato,Augusto Villanueva +6 more
TL;DR: The molecular heterogeneity of hepatocellular carcinoma, the intrinsic and extrinsic factors that stimulate tumour evolution and how this information can be leveraged to improve the clinical management of patients with this disease are discussed.
Journal ArticleDOI
The emerging role of cell-free DNA as a molecular marker for cancer management.
TL;DR: Recent advancements are explored and the current gaps in knowledge concerning each point of contact between cfDNA analysis and the different stages of cancer management are highlighted.
References
More filters
Journal ArticleDOI
Controlling the false discovery rate: a practical and powerful approach to multiple testing
Yoav Benjamini,Yosef Hochberg +1 more
TL;DR: In this paper, a different approach to problems of multiple significance testing is presented, which calls for controlling the expected proportion of falsely rejected hypotheses -the false discovery rate, which is equivalent to the FWER when all hypotheses are true but is smaller otherwise.
Journal ArticleDOI
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI
Fast gapped-read alignment with Bowtie 2
TL;DR: Bowtie 2 combines the strengths of the full-text minute index with the flexibility and speed of hardware-accelerated dynamic programming algorithms to achieve a combination of high speed, sensitivity and accuracy.
Journal ArticleDOI
Global cancer statistics, 2012
Lindsey A. Torre,Freddie Bray,Rebecca L. Siegel,Jacques Ferlay,Joannie Lortet-Tieulent,Ahmedin Jemal +5 more
TL;DR: A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.
Journal ArticleDOI
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
TL;DR: A marked increase in the use of international datasets for more highly evidenced-based changes in staging, and the enhanced use of nonanatomic prognostic factors in defining the stage grouping are notable.
Related Papers (5)
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Joshua D. Cohen,Lu Li,Yuxuan Wang,Christopher J. Thoburn,Bahman Afsari,Ludmila Danilova,Christopher Douville,Ammar A. Javed,Fay Wong,Austin Mattox,Ralph H. Hruban,Ralph H. Hruban,Christopher L. Wolfgang,Michael Goggins,Marco Dal Molin,Tian Li Wang,Tian Li Wang,Richard B.S. Roden,Richard B.S. Roden,Alison P. Klein,Alison P. Klein,Janine Ptak,Lisa Dobbyn,Joy Schaefer,Natalie Silliman,Maria Popoli,Joshua T. Vogelstein,J.D. Browne,Robert E. Schoen,Randall E. Brand,Jeanne Tie,Peter Gibbs,Hui-Li Wong,Aaron S. Mansfield,Jin Jen,Samir M. Hanash,Massimo Falconi,Peter J. Allen,Shibin Zhou,Chetan Bettegowda,Luis A. Diaz,Cristian Tomasetti,Cristian Tomasetti,Kenneth W. Kinzler,Bert Vogelstein,Anne Marie Lennon,Nickolas Papadopoulos +46 more
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda,Chetan Bettegowda,Mark Sausen,Rebecca J. Leary,Isaac Kinde,Yuxuan Wang,Nishant Agrawal,Nishant Agrawal,Bjarne Bartlett,Bjarne Bartlett,Hao Wang,Brandon Luber,Rhoda M. Alani,Emmanuel S. Antonarakis,Nilofer S. Azad,Alberto Bardelli,Henry Brem,John L. Cameron,Clarence Lee,Leslie A. Fecher,Leslie A. Fecher,Gary L. Gallia,Peter Gibbs,Dung T. Le,Dung T. Le,Robert L. Giuntoli,Michael Goggins,Michael D. Hogarty,Matthias Holdhoff,Seung-Mo Hong,Seung-Mo Hong,Yuchen Jiao,Hartmut Juhl,Jenny J. Kim,Giulia Siravegna,Daniel A. Laheru,Calogero Lauricella,Michael Lim,Evan J. Lipson,Suely Kazue Nagahashi Marie,George J. Netto,Kelly S. Oliner,Alessandro Olivi,Louise Olsson,Gregory J. Riggins,Andrea Sartore-Bianchi,Kerstin Schmidt,le-Ming Shih,Sueli Mieko Oba-Shinjo,Salvatore Siena,Dan Theodorescu,Jeanne Tie,Timothy T. Harkins,Silvio Veronese,Tian Li Wang,Jon D. Weingart,Christopher L. Wolfgang,Laura D. Wood,Dongmei Xing,Ralph H. Hruban,Jian Wu,Peter J. Allen,C. Max Schmidt,Michael A. Choti,Victor E. Velculescu,Kenneth W. Kinzler,Bert Vogelstein,Nickolas Papadopoulos,Luis A. Diaz,Luis A. Diaz +69 more